Shares of Hims & Hers Health (NYSE: HIMS) jumped following the company's first-quarter earnings report that once again announced surging revenue growth. That performance has helped the stock perform well this year, up about 40%.

Let's look at some recent comments from the CEO that caused the stock to dip, the company's recent quarterly results, and whether it's too late to buy the stock.

Hims & Hers CEO Andrew Dudum caused some controversy ahead of the company's earnings report when he came out on social media in support of pro-Palestinian college protests, while saying his company would be willing to hire the protesters.

Continue reading

Source Fool.com